Abstract
Acute Lymphoblastic Leukemia (ALL) is the most common cancer in children. The current childhood ALL treatment protocols achieve disease-free survival rates higher than 70%. Part of this success is due to the allocation of patients in different risk groups, according to pre-treatment prognostic factors. Initial treatment response, assessed by the quantification of residual leukemic cells, …